Fig. 7

RBGO1 ADC is effective within a 3D in vitro tumour model and effectively reduces tumour growth in a murine xenograft model of disease. a, b HEC1A cells cultured in low-adherent plates to enable spheroid formation, were incunbated with medium containing RBGO1 ADC (0.01–100 μg/ml), RBGO1 antibody (100 μg/ml) or mcF (200 nM) for 72 h. Cell viability was determined using the CellTiter 3D Glo Viability Assay and luminescence measured using a FLUOstar Omega microplate reader. Representative images of spheroids were acquired on a Zeiss Axio Imager 2 microscope. Relative cell viability plots were fitted using a 4-parameter logistic model (J). Data displayed are means of three independent experiments. c, d RBGO1 ADC (3 mg/kg), mcF (45 μg/kg) or PBS (Control) were adminstered intravenously to female athymic, nude mice bearing 5 mm HEC1A xenograft tumours on a twice weekly basis for 4 weeks. Bodyweights and tumour volumes were measured twice weekly. After 4 weeks, mice were sacrificed and organs harvested for evaluation of any systemic toxicity. Data displayed in are means of five animals with error bars omitted for clarity. Data were analyzed by ANOVA and Dunnett’s multiple comparison test. Treatments differ from control (PBS), *p < 0.05